aap Implantate (AAQ1) AI Stock Analysis

• Market Cap: €21.56M
• Dividend Yield: N/A
• Average Volume (3M): 1.88K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.50
• Revenue Growth: -0.59%
• EPS Growth: 24.03%
• Country: DE
• Employees: 87
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 13,909,306
• 10 Day Avg. Volume: 129
• 30 Day Avg. Volume: 1,880
• PEG Ratio: 0.09
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 1.03
• P/FCF Ratio: -8.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: €1.50 ▼(-3.85% Downside)

The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flow issues. Technical analysis shows a lack of strong momentum, and valuation metrics are unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a lower stock score.

aap Implantate Business Overview & Revenue Model

Company Description

aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.

How the Company Makes Money

aap Implantate generates revenue primarily through the sale of its orthopedic and trauma products to hospitals, clinics, and healthcare providers. Key revenue streams include direct sales of surgical implants and instruments, as well as ongoing supply contracts with healthcare facilities. The company also benefits from partnerships with distributors and collaborators in various regions, enhancing its market reach. Additionally, aap Implantate invests in research and development to continuously innovate its product offerings, which can lead to new revenue opportunities through the introduction of advanced technologies and solutions in the medical device market.

aap Implantate Financial Statement Overview

Summary

aap Implantate shows signs of revenue recovery with an 8.77% growth rate. However, profitability and cash flow remain significant challenges, with negative net profit, EBIT, and EBITDA margins. The balance sheet reflects reduced leverage, but profitability metrics are concerning. Overall, the company needs to address operational inefficiencies and improve cash flow management.

Income Statement

The company shows a positive revenue growth rate of 8.77% in the latest year, indicating some recovery. However, the net profit margin remains negative, reflecting ongoing profitability challenges. The EBIT and EBITDA margins are also negative, suggesting operational inefficiencies.

Balance Sheet

The debt-to-equity ratio has improved to 0.16, indicating a reduction in leverage. However, the return on equity remains negative, highlighting profitability issues. The equity ratio is stable, suggesting a reasonable level of financial stability.

Cash Flow

Free cash flow has improved significantly, with a growth rate of 454.96%. However, both operating and free cash flows are negative, indicating liquidity challenges. The ratios of cash flow to net income are not favorable, reflecting cash flow inefficiencies.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.20M	11.48M	11.52M	12.17M	9.33M
Gross Profit	10.67M	9.74M	10.58M	2.32M	-2.16M
EBITDA	-1.19M	-3.43M	-1.57M	-520.00K	-5.40M
Net Income	-3.63M	-5.13M	-2.56M	-2.52M	-8.94M
Balance Sheet
Total Assets	15.84M	19.47M	20.23M	22.95M	19.71M
Cash, Cash Equivalents and Short-Term Investments	2.46M	1.64M	236.00K	2.11M	885.00K
Total Debt	1.72M	5.29M	3.17M	5.08M	4.36M
Total Liabilities	5.38M	8.63M	7.40M	10.18M	9.41M
Stockholders Equity	10.46M	10.85M	12.83M	12.78M	10.29M
Cash Flow
Free Cash Flow	-1.45M	-3.40M	-2.38M	-2.99M	-4.09M
Operating Cash Flow	-1.12M	-2.99M	-1.89M	-2.47M	-3.67M
Investing Cash Flow	-327.00K	-397.00K	-469.00K	155.00K	-140.00K
Financing Cash Flow	2.22M	4.42M	475.00K	3.53M	1.77M

aap Implantate Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.56
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AAQ1, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.58, below the 50-day MA of 1.60, and below the 200-day MA of 1.62, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 37.24 is Neutral, neither overbought nor oversold. The STOCH value of 9.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:AAQ1.

aap Implantate Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M3V	80 Outperform	€45.14M	10.49	24.14%	3.89%	-5.72%	-25.19%
SBS	66 Neutral	€350.09M	20.71	―	2.09%	-1.64%	22.60%
GME	61 Neutral	€19.77M	11.14	8.35%	2.92%	-23.48%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AAQ1	45 Neutral	€21.56M	―	-34.28%	―	-0.59%	24.03%